

FIGURE 1





FIGURE 2






FIGURE 3




(-) Betaxolol



(+) Betaxolol

FIGURE 4



SUBSTITUTE SHEET (RULE 26)


09/913762

WO 00/49416

PCT/GB00/00585



5/22

FIGURE 5



SUBSTITUTE SHEET (RULE 26)

FIGURE 6a



7/22




FIGURE 6b

FIGURE 7a

9/22

FIGURE 7b

10/22

FIGURE 7c





FIGURE 8a






Figure 9




a)




b)




c)




d)




b)



d)



a)



c)

SUBSTITUTE SHEET (RULE 26)

FIGURE 108




FIGURE 10c




FIGURE 11




FIGURE 12





FIGURE 13


FIGURE 14

CAM β_2 AR | Renilla Luciferase

(-) Antagonist (+) Antagonist



Upregulation monitored by increased luciferase activity in cells



Paramete	Value	SE	Lower CL	Upper CL	Paramete	Value	SE	Lower CL	Upper CL
a (Iso ave)	107.98	4.99006	96.4729	119.4871	a (ave bet)	91.99781	4.066952	82.6194	101.3762
c (Iso ave)	3.04E-06	8.74E-07	1.57E-06	5.9E-06	c (ave bet)	1.16E-07	2.64E-08	6.85E-08	1.96E-07
d (Iso ave)	263.6671	9.532958	241.684	285.6501	d (ave bet)	194.6117	3.153874	187.3389	201.8846
b (Iso ave)	1	0	1	1	b (ave bet)	1	0	1	1




FIGURE 15

Paramete	Value	SE	Lower CL	Upper CL
a (ave sot)	91.61328	3.703476	83.07304	100.1535
c (ave sot)	1.59E-06	4.07E-07	8.77E-07	2.87E-06
d (ave sot)	208.4677	5.759934	195.1852	221.7501
b (ave sot)	1	0	1	1

21/22

A



B




FIGURE 16

22/22





FIGURE 17